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КОРЕКЦІЯ ПОРУШЕНЬ В СИСТЕМІ ГЕМОСТАЗУ ПРИ НЕВИНОШУВАННІ  
В І ТРИМЕСТРІ ВАГІТНОСТІ 
Резюме. Аналіз ефективності терапії невиношування вагітності з використанням дуфастону та флоген-
зиму показав, що їх застосування сприяє нормалізації показників системи гемостазу, зниженню кіль-
кості акушерських та перинатальних ускладнень. 
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The problem of miscarriage of pregnancy remains 
topical one despite the progress achieved in the 
treatment and prevention of complications of 
pregnancy. The frequency of of this pathology is quite 
high and there is no tendency to decrease. It consti-
tutes 10-20% of all pregnancies and 55% – after 3 
miscarriages of pregnancy (miscarriage accustomed). 
Percentage of miscarriages increases significantly 
after interruption of previous pregnancies. Thus, after 
the 1st spontaneous abortion it is 23%, after 2 
miscarriages – 29%, after 3 miscarriages – up to 55% 
[1]. 
Purpose of the research. Evaluating the 
effectiveness of the proposed treatment of the miscar-
riage in the I-st trimester of pregnancy of the primary 
and secondary hemostasis, fibrinolytic activity of 
blood, markers of DIC-syndrome. 
Material and methods. We have analyzed the 
effectiveness of the proposed treatment in 46 women 
with threatened miscarriage in the first trimester (the 
main group). The control group consisted of 50 
women with miscarriage in the first trimester who 
took generally accepted complex therapy. The groups 
were statistically similar. State of platelet-vascular 
hemostasis stage was estimeted by adhesive platelet 
percentage (APP), as well as by spontaneous platelet 
aggregation index (SPAI). Total coagulative potential 
of blood plasma (recalcification time (RT), thrombin 
time (TT), prothrombin time (PT) and activated par-
tial thromboplastin time (APTT)), fibrinolytic activ-
ity of plasma, potential activity of plasminogen, an-
tiplasmins, fibrinogen level (FGL), activity of an-
tithrombin III (AT-III), concentration of soluble fi-
brin monomer complexes (SFMC) in blood and early 
fibrinogen degradation products (EFDP) in urine and 
urokinatic urine activity (UUA) were determined ac-
cording to the instructions to sets of reagents pro-
duced by the Scientific Industrial Company 
“SIMKO-Ltd”, Lviv. 
Discussion of the results. The data of our previ-
ous studies of the system of hemostasis in women 
with miscarriage in the first trimester pointed to sig-
nificant changes in the first place of the primary he-
mostasis, that caused a rise in the general blood coag-
ulative potential against the background of some  de-
crease of fibrinolytic activity and activity of antico-
agulative system and also of normal indices of prote-
olytic system [2-4]. 
In connection with the abnormalities discovered 
in the system of hemostasis in women with miscar-
riage of pregnancy  it became necessary to add medi-
cations that affect the aggregation blood state to the 
complex of therapeutic remedies [5, 6]. We have cho-
sen Enzyme preparation phlogenzym, which is a spe-
cifically selected combination of two complementary 
enzymes (Bromelain 90 mg, 48 mg Trypsinum) with 
Rutinum of plant origin (Rutoside 100 mg). The drug 
significantly improves microcirculation. It is able to 
reduce thrombosis and intensify processes of fibrinol-
ysis; it inhibits platelet aggregation, produces an ef-
fect on adhesive molecules and increases the ability 
of erythrocytes to change their shape [6]. 
Correction of treatment to pregnant women with 
chronic form of DIC-synrome against the background 
of threatened abortion was performed as follows: 
1. Duphaston – in case of threatened abortion 
was administered only once 40 mg, then 10 mg every 
8 hours until  disappear of  threatening symptoms. 
2. Chophytol – the drug potentiates the action of 
antiplatelet agents, it was administered as indicated in 
Table 2 3 times a day before meals for 2-3 weeks. 
3. Phlohenzym – 2 tablets 30-60 minutes befoe 
meals, with plenty of fluid (up to 200 mL) three times 
a day for 10-14 days with transition to maintenance 
therapy: 1 tablet three times a day for 1 month. 
All pregnant women tolerated the proposed 
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treatment well, none of them had unpleasant subjec-
tive sensations. All pregnancies in the main group 
were preserved, in the control group – 3 pregnancies 
were interrupted  up to 12 weeks. 
The course of the proposed therapy resulted in 
normalization of hemostatic indices. Studying the to-
tal hemocoagulative potential after treatment, we ob-
served extension of its principal temporal character-
istics and increased activity of anticoagulative system 
(table 1). 
Thus, the extension of RT to 28.3 seconds com-
pared with a group of women who were convention-
ally treated (p<0.05) was indicative of retardation of 
an internal way of coagulation. Reliable growth of PT 
1.3 times (p<0.05) testified to the presence of a weak 
trend towards inhibition of external way of blood 
clotting. We also registered a decrease in activity of 
fibrinogenesis, that manifested itself in lengthening 
TT 1.56 times (p<0.05). A growth of APTT 1.5 times 
proved once again the fact of inhibition of hemocoag-
ulative potential, especially as it was in conditions of 
increased activity of AT-III (p<0.05). 
Under the influence of combined therapy with 
phlogenzym positive changes have taken place in the 
system of platelet-vascular hemostasis, the indices of 
which (SPAI – Spontaneous Platelet Aggregation In-
dex and PAP – Platelet Adhesion Percentage) de-
creased respectively 2.1 and 2.65 times relatively to 
the comparison group (p<0.05). Taking into consid-
eration that activation of this phase of hemostasis, ac 
cording to our research, caused the development of 
chronic subclinical forms of DIC-syndrome in preg-
nant women with miscarriage in the first trimester, the 
use of the proposed therapeutic complex by this con-
tingent of women will enable them to reduce the risk 
of complications mentioned above. Especially as we 
have registered a reliable decrease in blood concen-
trations of markers of DIC-syndrome (table 2). It was 
confirmed by the decline of SFMC 4.5 times 
(p<0.05); FDP in urine 9.7 times (p <0.05) and 
growth of Luki-Lorand factor activity by 12.89% 
(p<0.001).Changes of indices of fibrinolytic system 
Table 1 
Changes of the total coagulative potential in pregnant women with threatening miscarriage who took 
the proposed complex of treatment (x±Sx) 
 
Indices studied 
Pregnant women 
who took the proposed 
course of treatment 
n=46 
Pregnant women with miscarriage 
who took the conventional treat-
ment 
n=50 
Recalcification time, sec 118.3±3.71 
р<0.001 
90.01±4.06 
Prothrombin time, sec 23.40±1.27 
p<0.05 
18.10±1.64 
 
Thrombin time, 
sec 
19.20±1.52 
p<0.05 
12.69±1.82 
 
Activated Partial Throm-
boplastin Time, sec 
47.3±2.72 
p<0.001 
29.95±1.62 
 
Antithrombin ІІІ, % 93.62±2.06 
p<0.05 
85.93±2.91 
Note: p – the degree of reliability of differences of indices in pregnant women with miscarriage who took the proposed 
course of treatment and women with generally accepted treatment 
Table 2 
Changes of indices in the state of intra-vascular hemocoagulation in women with miscarriage of preg-
nancy who took the proposed complex of treatment (x±Sx) 
Indices studied Pregnant women who took the 
proposed course of treatment 
n=46 
Pregnant women with miscarriage 
who took the conventional treatment 
n=50 
Concentration of  SFMC (Solu-
ble Fibrin-Monomer Com-
plexes) in blood plasma, mkg/ml 
8.07±1.62 
р<0.001 
34.00±2.80 
Concentration of FDP (Fibrin 
Degradation Product) in urine, 
mkg/ml 
0.83±0.21 
р<0.001 
7.46±1.05 
XIII factor Activity, % 68.31±3.81 
р<0.05 
55.42±3.63 
Note: p – the degree of reliability of differences of indices in pregnant women with miscarriage who took the proposed 
course of treatment and women with generally accepted treatment 
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indicate to the improving of the rheological properties 
of blood in women after the proposed treatment (table 
3). 
Increase of urokinatic synthesis in JAA (jux-
taglomelular apparatus) of kidneys led to the activa-
tion of Hageman-dependent mechanisms of fibrinol-
ysis, which increased in comparison with the control 
group 1.4 times (p<0.05). Indices NEFA and EFA, 
which testify to the presence of parabasal violations 
with lability of mast cells and denudation of vessels 
of microvascular flow, though not significantly in-
creased, but did not reach the level of reliability 
(p>0.05). 
Thus, we can conclude that the proposed com-
plex of therapeutic measures leads to the arrest of 
chronic DIC-syndrom in women with miscarriage. 
The analysis of further course of gestational pe-
riod, labor and the postpartum period showed that the 
proposed therapeutic complex had led to a decrease 
in the frequency of obstetric complications. Percent-
age of preeclampsia decreased 2.3 times (p<0.05), 
threatened abortions in later stages – 2.2 times 
(p<0.05). The state of fetus has significantly im-
proved, that was evidenced by reducing of percentage 
HDF (Hageman Dependent Fibrinolysis) and FGR 
(Fetus Growth Retardation) – respectively 2.2 and al-
most 3 times (p<0.05). 
The total number of abnormal labors in the main 
group has also reduced. Index of premature rupture of 
fetus membranes was less almost by 22.2% than indi-
ces in the comparison group (p<0.05). 
Anomalies of labor activity (mainly primary and sec-
ondary weakness) and premature separation of nor-
mally located placenta were observed respectively 3.2 
and 4.9 times less than in women in childbirth who 
took the conventional treatment (p<0.05). The latters 
often manifested pathology of the postpartum period 
that was associated with an abnormality of attachment 
of afterbirth (16.42±4.53% to 4.55±2.57%, p<0.05), 
that required manual separation of placenta and its re-
moval and manual examination of the uterus. The in-
creased volume of blood loss (0.8% of body weight) 
was 4 times more observed in women in childbirth of 
the comparison group. 13 (19.40±4.83%) women in 
the same group brought child in the world by cesarean 
section; only 3 (4.48±2.53%) of them - in a planned 
term. In the main group the frequency of operative 
delivery was 6.06±2.94% (p<0.05). 
The course of the postpartum period was also 
more favourable in women in childbirth, who took the 
proposed correction of hemostasis in small terms. 
They rarely manifested subinvolution of uterus (re-
spectively 3.03±2.11% and 14.93±4.35%, p<0.05). 
No woman was diagnosed with development of endo-
metritis, while in the comparison group it occurred in 
2 (2.99±2.08%) women surveyed. Parting of sutures 
on perineum (p<0.05) was registered three times less 
and infiltrative mastitis developed in one case
 
Table 3 
Changes of indices of fibrinolytic system of blood in women with miscarriage who took the proposed 
course of treatment (x±Sx) 
Indices studied Pregnant women with miscar-
riage who took the proposed 
course of treatment 
n=46 
Pregnant women with miscar-
riage who took the conventional 
treatment 
n=50 
TFA,  
Е440/ml/hour Total Fibrino-
lytic Activity 
17.541.75 13.321.92 
NEFA,  
Е440/ml/hour Non-enzy-
matic Fibrinolytic Activity 
5.780.72 4.410.82 
EFA,  
Е440/ml/hour (Enzymatic Fi-
brinolytic Activity) 
11.761.08 8.911.12 
Concentration of fibrinogen 
in blood plasma, g/l 
3.200.21 3.160.29 
UUA,  
Unit Urokinatic Urine Activ-
ity 
35.871.24 32.291.57 
Potential activity of Plasmin-
ogen, min 
19.861.35 19.641.63 
Hageman-dependent Fibri-
nolysis, min 
29.821.07 
р0.05 
21.322.05 
Note: p – the degree of reliability of differences of indices in pregnant women with miscarriage who took the pro-
posed course of treatment and women with generally accepted treatment 
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(1.52±1.50%) against four (5.97±2.89%, p>0.05). 
Observations of women who were a part of the 
clinical groups further showed that 30 (45.46 ± 
6.13%) examined women of the main group retained 
lactation up to 6 months. Women of the comparison 
group only in 17 (25.37±5.32%) cases retained lacta-
tion to 4-6 months and only 6 (8.96±3.49%) women 
retained it after 6 months (p<0.05). 
After the administered therapy we observed im-
provement in the state of newborns and their physical 
development. Weight of babies in the main group al-
most did not differ from weight of babies in the con-
trol group. In the group of women who took the cor-
rective therapy, the state of newborns was estimated 
as “satisfactory” in 74.24±5.38% of cases, signs of 
asphyxia were found in 25.75±5.38%. Children born 
with severe asphyxia were not recorded. The exam-
ined women who took the conventional treatment had 
53.73±6.09% of children born with asphyxia, born 
with severe asphyxia – 2.99±2.08% of cases 
(p<0.05).There was no perinatal mortality of the 
women surveyed. 
Conclusion. Thus, analyzing the results of the 
research, we can conclude that our proposed therapy 
with duphaston and phlogenzym promotes normali-
zation of hemostatic system and reduction of the 
number of obstetric and perinatal complications. 
Perspective of further investigations. In-depth 
study of changes in the hemostatic system in women 
with miscarriage in the I-st trimester of pregnancy 
and correction of infringements will have practical 
significance for the development of complex 
treatments threats pregnancy and prevention of 
perinatal complications. 
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КОРРЕКЦИЯ НАРУШЕНИЙ В СИСТЕМЕ 
ГЕМОСТАЗА ПРИ НЕВЫНАШИВАНИИ В І 
ТРИМЕСТРЕ БЕРЕМЕННОСТИ 
Резюме. Анализ эффективности терапии невына-
шивания беременности с использованием дуфас-
тона и флогензима показал, что их применение 
способствует нормализации показателей системы 
гемостаза, снижению акушерских и перинаталь-
ных осложнений. 
Ключевые слова: невынашивание беременно-
сти, гемостаз, дуфастон, флогензим. 
CORRECTION OF DISORDERS IN THE SYS-
TEM OF HEMOSTASIS IN CASE OF MISCAR-
RIAGE IN THE I-ST TRIMESTER OF PREG-
NANCY 
Abstract. Analysis of the effectiveness of therapy of 
miscarriage using duphaston and flogenzym showed 
that their use contributed to normalization of the he-
mostatic system and to decline a number of obstetric 
and perinatal complications. 
Key words: miscarriage, hemostasis, duphaston, 
phlogenzym. 
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